



If you would like to share news or information with our readers, please send the unique stories, business

news organization events, and school news to us including your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com

or contact

John Robbins 281-965-6390

Jun Gai 281-498-4310

Publisher: Wea H. Lee
President: Catherine Lee
Editor: John Robbins

Address: 11122 Bellaire Blvd.,
Houston, TX 77072
E-mail: News@scdaily.com



Inside C2

Southern DAILY

Southern Daily News is published by Southern News Group Daily

Monday, December 13 2021

China supports debt issuance by developers to fund acquisitions - Sec

SHANGHAI, Dec 10 (Reuters) - A Chinese self-regulatory body overseeing the interbank market will support debt issuance by qualified developers to fund acquisitions of real estate projects and finance completion of unfinished buildings, the official Securities Times reported on Friday.

The National Association of Financial Market Institutional Investors (NAFMII) held a meeting with Chinese developers on Friday at which it said individual risk cases won't affect the normal financing functions of the market over the medium to long term, according to newspaper.

This is the latest sign that China is marginally relaxing financing conditions for developers to prevent the financial trouble of heavily-indebted China Evergrande Group (3333.HK) from triggering a collapse of the property sector, as well as a sharp slowdown of the economy. However, NAFMII will prioritise support to those developers that operate in line with China's real estate policies, the newspaper said, suggesting Beijing won't reverse its deleveraging campaign.

Developers including China Merchants Shekou Industrial Zone Holdings Co (001979.SZ) plan to issue debt instruments via the interbank market in the near term to fund mergers and acquisitions, the newspaper said.



Boosters significantly restore protection vs Omicron, UK says

LONDON, Dec 10 (Reuters) - Booster COVID-19 shots significantly restore protection against mild disease caused by the Omicron variant, in part reversing an otherwise steep drop in vaccine effectiveness, the UK Health Security Agency said on Friday.

The early findings from a real-world analysis are some of the earliest data on the protection against Omicron outside of lab studies, which have shown reduced neutralising activity against Omicron. read more
"These early estimates should be treated with caution but they indicate that a few months after the second jab, there is a greater risk of catching the Omicron variant compared to Delta strain," said Dr Mary Ramsay, Head of Immunisation at the UKHSA, adding that protection against severe disease was expected to remain higher.

"The data suggest this risk is significantly reduced following a booster vaccine, so I urge everyone to take up their booster when eligible."
In an analysis of 581 people with confirmed Omicron, two doses of AstraZeneca (AZN.L) or Pfizer-BioNTech (PFE.N), vaccines provided

much lower levels of protection against symptomatic infection compared with what they provide against Delta.

However, when boosted with a dose of Pfizer vaccine, there was around 70% protection against symptomatic infection for people who initially received AstraZeneca, and around 75% protection for those who received Pfizer.

Say YES to affordable health-care plans for Texans
It's easy to say YES to a healthcare plan with affordability, flexible options, the largest hospital network, and free preventive care.

That compares with estimated protection against infection from Delta following a booster of around 90%.

UKHSA reiterated it found that Omicron had a growth advantage over Delta, and a 3-to-8 fold increased risk of reinfection.

It said two UK studies which have yet to be presented publicly and three international studies suggested Omicron



gave a 20 to 40-fold reduction in neutralising antibodies compared with the viruses used to develop vaccines.

UKHSA said that while no cases of Omicron had yet resulted in hospitalisation or death, the was insufficient data to assess the severity of Omicron.

At current growth rates, Omicron would account for more than 50% of all COVID-19 infections by mid-December, UKHSA said, with Britain exceeding one million infections by the end of the month, as new measures come into force in England to slow the spread of Omicron.

"Rising cases of the Omicron variant

A person receives a dose of the Pfizer coronavirus disease (COVID-19) vaccine at a vaccination site at the Westfield shopping centre in London, Britain, December 3, 2021. REUTERS/Henry Nicholls

coupled with the new data today should be a wake-up call for those who haven't yet had their booster or, indeed, any vaccine," National Health Service medical director Stephen Powis said.



李淑惠
Sue Lee

萬德福保險

地址: 9600 Bellaire Blvd., #111, Houston.TX 77036

長者健康保險medicare、人壽保險、長照保險、
年金健康保險(給不符合ACA條件的人)

代理數家知名公司 (服務親切 誠信可靠)

歡迎獨立agent
加入團隊

281-758-9152 / 346-364-8405

Email: Wonderfulsuelee@gmail.com / <http://suelee.agentmedicareplans.com>

China outbound tourism set to jump more than 25% this year - state media

BEIJING, (Reuters) - Chinese outbound tourism numbers are set to jump by more than 25% this year from 2020 but remain “basically at a standstill” compared to pre-pandemic levels, state broadcaster CCTV reported on Monday, citing official projections.

The dramatic drop in travellers from China, the world’s most populous nation, since the rapid spread of coronavirus early last year, has left a \$255 billion annual spending hole in the global tourism market. A total of 25.62 million Chinese tourist trips overseas are expected to be made in 2021, CCTV said, citing an annual report on outbound tourism from the China Tourism Academy, part of the Ministry of Culture and Tourism.

That is up from 20.334 million in 2020, which was itself an 86.9% plunge from a year earlier as the coronavirus outbreak led to severe restrictions on global travel. rojection, which includes trips to special administrative regions of China such as the gambling hub of Macau, will still be well below annual numbers of over 100 million before the pandemic hit, CCTV noted.

Macau, a former Portuguese colony, has become a “bright spot” for out-bound tourism from mainland China due to effective virus prevention and control measures, CCTV said.

The pace of recovery in 2022 will depend on how other destinations handle tourism, it added.

China’s National Immigration Administration said this month it would continue to guide citizens not to go abroad for non-urgent and non-essential reasons. China’s state planner, the National Development and Reform Commission (NDRC), has put out several statements since Tuesday night that it was studying ways to guide prices back to a “reasonable range” and to crack down on “excessive profits” at coal firms. [read more](#)

On Friday, the NDRC said it held a meeting with large state-run companies including oil refiner Sinopec, aluminium giant Chinalco and steelmaker China Baowu on “rational” energy usage by industry on Thursday and said they should take the lead in energy-saving and carbon reduction.



People walk along Nanjing Pedestrian Road, a main shopping area, during the Labour Day holiday, following the outbreak of the coronavirus disease (COVID-19), in Shanghai, China May 5, 2021. REUTERS/Aly Song/File Photo



Editor’s Choice



Cristian Linares, 8, reacts as he receives a dose of the Sinopharm vaccine against the coronavirus, in La Paz, Bolivia. REUTERS/Claudia Morales



Members of the ships company stand in the ‘Procedure Alpha’ position on the flight deck of the Royal Navy aircraft carrier HMS Queen Elizabeth, as it approaches Her Majesty’s Naval Base (HMNB) Portsmouth, following her seven month deployment leading Carrier Strike Group 21, in Portsmouth, Britain. REUTERS/Henry Nicholls



Farmers listen to a speaker at the protest site near the Delhi-Haryana border, India. REUTERS/Anushree Fadnavis



A Christmas tree sits in the back of a truck in Durango, Colorado. REUTERS/Shannon Stapleton



Musmin, 55, a local who lost his grandchild, rests on a rock while visiting the area that he believes is where his grandchild is buried following the Mount Semeru volcano eruption in Sumbawuluh, Candipuro district, Lumajang, East Java province, Indonesia. REUTERS/Willy Kurniawan



A diver wearing Santa Claus costume swims in a large fish tank with fish, as visitors wearing protective face masks look on, during an underwater performance for the Christmas celebration at Hakkeijima Sea Paradise in Yokohama, south of Tokyo, Japan. REUTERS/Issei Kato

A Chewing Gum That Could Reduce SARS-CoV-2 Transmission?



Key Points

In experiments using saliva samples from COVID-19 patients, the gum, which contains the ACE2 protein, neutralized the virus, according to research led by School of Dental Medicine scientists.

Compiled And Edited By John T. Robbins, Southern Daily Editor


A chewing gum laced with a plant-grown protein serves as a “trap” for the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission, according to a new study.

The work, led by Henry Daniell at Penn’s School of Dental Medicine and performed in collaboration with scientists at the Perelman School of Medicine and School of Veterinary Medicine, as well as at The Wistar Institute and Fraunhofer USA, could lead to a low-cost tool in the arsenal against the COVID-19 pandemic. Their study was published in the journal Molecular Therapy.

“SARS-CoV-2 replicates in the salivary glands, and we know that when someone who is infected sneezes, coughs, or speaks some of that virus can be expelled and reach others,” says Daniell. “This gum offers an opportunity to neutralize the virus in the saliva, giving us a simple way to possibly cut down on a source of disease transmission.”

Vaccinations for COVID-19 have helped change the course of the pandemic but haven’t stamped out transmission. Even people who are fully vaccinated can still become infected with SARS-CoV-2 and, according to recent research, can carry a viral load similar to those

who are unvaccinated.




Penn Dental Medicine’s Henry Daniell and colleagues used a plant-based protein drug production platform to grow the ACE2 protein, which was then infused in chewing gum. By either blocking the ACE2 receptor or binding to the SARS-CoV-2 spike protein, the ACE2 in the gum appears to be able to reduce viral entry into cells. (Image: Courtesy of the researchers)

Prior to the pandemic, Daniell had been studying the angiotensin-converting enzyme 2 (ACE2) protein in the context of treating hypertension. His lab had grown this protein, as well as many others that may have therapeutic potential, using a patented plant-based production system. By bombarding

plant material with the DNA of target proteins, they coax plant chloroplasts to take up the DNA and begin growing the proteins. The plant material, freeze-dried and ground-up, could be used as a means of delivering the protein. This system has the potential to avoid the usual obstacles to protein drug synthesis: namely, an expensive production and purification process.

Daniell’s past work on ACE2 proved fortuitous in the context of the COVID-19 pandemic. The receptor for ACE2 on human cells also happens to bind the SARS-CoV-2 spike protein. Other research groups have shown that injections of ACE2 can reduce viral load in people with severe infections. Meanwhile, another line of work by Daniell and Penn Dental Medicine colleague Hyun (Michel) Koo has involved research to develop a chewing gum infused with plant-grown proteins to disrupt dental plaque. Pairing his insights about ACE2 with this technology, Daniell wondered if such a gum, infused with plant-grown ACE2 proteins, could neutralize SARS-CoV-2 in the oral cavity.



Henry Daniell of Penn’s School of Dental Medicine

To find out, he reached out to Ronald Collman at Penn Medicine, a virologist and


pulmonary and critical care doctor whose team, since the early stages of the pandemic, had been collecting blood, nasal swabs, saliva, and other biospecimens from COVID patients for scientific research.

“Henry contacted me and asked if we had samples to test his approach, what kind of samples would be appropriate to test, and whether we could internally validate the level of SARS-CoV-2 virus in the saliva samples,” Collman says. “That led to a cross-school collaboration building on our microbiome studies.”

To test the chewing gum, the team grew ACE2 in plants, paired with another compound that enables the protein to cross mucosal barriers and facilitates binding, and incorporated the resulting plant material into cinnamon-flavored gum tablets. Incubating samples obtained from nasopharyngeal swabs from COVID-positive patients with the gum, they showed that the ACE2 present could neutralize SARS-CoV-2 viruses.

Those initial investigations were followed by others at The Wistar Institute and Penn Vet, in which viruses, less-pathogenic than SARS-CoV-2, were modified to express the SARS-CoV-2 spike protein. The scientists observed that the gum largely prevented the viruses or viral particles from entering cells, either by blocking the ACE2 receptor on the

cells or by binding directly to the spike protein.



Finally, the team exposed saliva samples from COVID-19 patients to the ACE2 gum and found that levels of viral RNA fell so dramatically to be almost undetectable. The research team is currently working toward obtaining permission to conduct a clinical trial to evaluate whether the approach is safe and effective when tested in people infected with SARS-CoV-2.

“Henry’s approach of making the proteins in plants and using them orally is inexpensive, hopefully scalable; it really is clever,” Collman says.

Though the research is still in early stages of development, if the clinical trials prove the gum is safe and effective, it could be given to patients whose infection status is unknown or even for a dental check-ups when masks must be removed, to reduce the likelihood of passing the virus to caregivers.

“We are already using masks and other physical barriers to reduce the chance of transmission,” says Daniell. “This gum could be used as an additional tool in that fight.” (Courtesy <https://penntoday.upenn.edu/news>)

Related

COVID-19 Omicron Variant Detected In Houston Wastewater



‘Omicron in Houston is cause for concern but not panic,’ Houston’s chief medical officer said. (Photo/Godofredo A. Vásquez, Houston Chronicle / Staff photographer)

The Stadler lab at Rice University’s Brown School processes approximately 200 samples of waste water to figure out which variant and what amount of the COVID-19 virus is found. Health authorities say a sample from Houston’s wastewater system tested positive for the Omicron variant of COVID-19 on Monday, the same day a woman separately tested positive for the variant in northwest Harris County.

In Houston, there’s no confirmed case just yet — but the positive wastewater indicates one could crop up soon. Mayor Sylvester Turner in a press release Monday said the

news is an important reminder to schedule a booster shot for the COVID-19 vaccine.

“Vaccines help protect us, our loved ones, friends, and colleagues in the work environment,” Turner said. “As the holidays approach, I encourage everyone to remain vigilant about their health and safety.”

Facilitating omicron here in Texas: Our abysmal vaccination rates. Only 55% 2 shots, but in Central Texas or East Texas only 40%, many counties 30%. Booster shots? You can imagine...Since the 2010s Texas has been the epicenter of the anti-vaccine movement <https://t.co/ml2mz3B-CY9>

— Prof Peter Hotez MD PhD (@PeterHotez) December 7, 2021

In Harris County, only 56 percent of the county’s 4.6 million people are considered fully vaccinated, according to the Houston Chronicle.

The Omicron finding came during routine sweeps of the city’s wastewater for the virus that causes COVID-19, according to the Houston Health Department. That testing includes several variants of the virus, as traces of it can be found in feces of those who are infected. City health officials were also testing wastewater outside a few elementary schools across Houston, according to KHOU’s Ugochi Iloka.

HAPPENING NOW: Crews with @HoustonHealth are testing waste water at local schools for Covid-19 variants like Omicron and Delta. They plan to test near 30 schools in the Houston area today @KHOU [pic.twitter.com/veKMRPNbT](https://twitter.com/veKMRPNbT) — Ugochi Iloka KHOU (@UgochiKHOU) December 7, 2021

The consensus on the Omicron variant’s potential impact remains unsettled. Health authorities in the federal government are working to determine if it is any more transmissible or lethal than other strains, according to the Houston Health Department.



“Omicron in Houston is cause for concern but not panic,” said Dr. David Persse, Houston’s chief medical officer. “It’s important to remember that vaccination is our best tool to reduce cases, prevent serious illness and death, and slow the emergence of new variants.”

The city of Houston provides free COVID-19 vaccines, including boosters, to anyone 5 and older. A list of vaccination sites can be found on the city’s website. (Courtesy The Houston Chronicle)

COVID Immunity Levels Can Be Measured In 15 minutes

Houston Startup Develops Ground Breaking COVID Immunity Test

Compiled And Edited By John T. Robbins, Southern Daily Editor



A team of researchers at Brevitest has developed a quick, finger-stick blood test to determine immunity to COVID-19, using a small, desktop device they invented that conducts the test using robotic technology with proprietary testing cards used to analyze the blood samples. Photographed at their offices, Monday, Nov. 29, 2021, in Houston. (Photo/Mark Mulligan, Houston Chronicle / Staff photographer)

A Houston startup has developed a revolutionary COVID-19 test that can measure immunity levels and determine whether or when people need a new vaccine or booster to protect themselves from the disease.

The instant test could be widely available soon, if the Food and Drug Administration grants the new device fast-track approval. Knowing personal immunity levels could become increasingly important in the face of new variants, like omicron, when people need to decide whether or when they need a new vaccine or booster shot.

The affordable, first-of-its-kind fingerstick blood test is offered by Brevitest, a company developed at Fannin Innovation Studios, a life sciences incubator in River Oaks. Researchers invented a new method for measuring antibodies, using cloud computing to process results and delivering them in 15 minutes to determine if an immune system needs a boost.

Doctors, companies and public health officials can use the tests to determine the COVID immunity levels for individuals, workforces or entire communities so they can employ more targeted strategies for slowing the disease. Since the technology is protected by patents, Brevitest can license the unique device and potentially become one of the most significant startups to emerge from Houston’s life sciences community in a decade.



Leo Linbeck III, the CEO and co-founder of Brevitest, said his company’s technology builds on recent

research that has determined how many antibodies per unit of blood people need to fight off or minimize a coronavirus infection. The new test lets people know where they stand, whether from a vaccination or natural immunity to determine if they need a booster or difference vaccine Brevitest can adapt the test to detect antibodies for any variant, including omicron. Once approved, the company could begin deploying the device across the country within a few months to carry out millions of tests a week.

The Centers for Disease Control and Prevention — worried about vaccines wearing off — recently authorized COVID-19 booster shots six months after vaccination, prioritizing those over 65 years old. But individual needs vary widely and some people lose antibodies quicker than others.

“Everyone’s biology is different, and the data seems to indicate that it could be anywhere from three months to 12 months when you see the antibody level begin to wane,” Linbeck told me. “That’s particularly problematic for older people who tend to have less of an immune response or those who are immunosuppressed or immunocompromised.”



Fast tests to detect SARS-CoV-2 antibodies have been on the market since early in the pandemic, but they only offer

positive or negative results and don’t measure antibodies.

Doctors who have patients with weak immune systems have relied on a precise blood test called an enzyme-linked immunosorbent assay, or ELISA, that are currently done at central laboratories. But those results can take several days to return.

“We’re trying to build a point-of-care ELISA because the way we look at it, either you can have accuracy that will take time or you can have speed, and then you lose accuracy,” ex-

plained Dr. Dev Chatterjee, a co-founder and co-inventor. “The question we asked ourselves is, is there a way we can marry the two?”

The Brevitest device allows a technician to place a small blood sample on a custom-designed cartridge, which is inserted into a shoebox-sized device that produces digital diagnostic data, the same as the precision test.

The device sends the data to the cloud, where it is processed using proprietary software Linbeck wrote. Patients receive an alert and can access the results with their phones, which also allows them to compare their result with the latest COVID immunity data.

The new company can make a profit at the same \$43 reimbursement rate insurance companies pay for a central lab test, Linbeck said. Brevitest is offering tests at its lab in Houston.



Until recently, researchers were unsure how many antibodies someone needed to fend off the virus. But that changed in September when the journal Nature Medicine published a new study that used the World Health Organization standard to measure antibody levels and showed a correlation between antibody levels and infection rates.

Healthy people can use the test to determine if they need a booster or should wait a few months to take full advantage of their vaccine or illness-induced antibodies.

“There’s some evidence that if you wait longer and you let your antibody count drop, when you get that vaccine (booster), you get a bigger bump. You get more antibody production than you would if you had taken it while you still have active antibody response,” he added. Linbeck, Chatterjee and co-inventor Dr. Atul Varadhachary founded Brevitest in 2013 to create an office-based blood testing system that would generate precision blood test results quicker. The National Institutes of Health provided a grant during the test’s early development, and the Centers for Disease Control asked Brevitest to develop an Ebola test during the 2014 outbreak.



Aquinas Companies CEO Leo Linbeck works on code for a BreviTest analyzer, BreviTest is one of the

startup companies helped by Fannin Innovation Studio which helps researchers and scientists with life science product develop-

ment July 7, 2016, in Houston.

(Photo/James Nielsen / Houston Chronicle) Chatterjee and Varadhachary said the scientific challenge was far more formidable than expected. Designing a new cartridge that prepared the blood for scanning in a new way took years. Linbeck, an engineer, worked on reliability and durability to meet exacting medical standards. “Once you actually get down to developing for the real world versus creating something for the lab, there is a whole ocean of problems that you have to solve,” Chatterjee explained.

When the COVID-19 pandemic began, the company refocused on measuring SARS-CoV-2 antibodies.

Brevitest is one of four life science start-ups spun out of Fannin Innovation Studio, Linbeck’s biotechnology development company. He is best known as the executive chairman of the Linbeck Group, a construction company founded by his grandfather that built many of the structures at the Texas Medical Center. Linbeck and Varadhachary started Fannin to commercialize discoveries made at TMC. But Brevitest was Fannin’s homegrown effort to address the lengthy delay in returning accurate blood test results, a goal of many companies.



A team at Brevitest has developed a quick, finger-stick blood test to determine a person’s immunity to Covid-19 using a small, desktop device they invented that conducts the test using robotic technology with proprietary testing cards used to analyze the blood samples. Photographed at their offices, Monday, Nov. 29, 2021, in Houston. (Photo/Mark Mulligan, Houston Chronicle / Staff photographer)

The most famous attempt to develop a rapid diagnostic device is TheraNas, a Silicon Valley-based company that promised a full blood workout from a tiny vial using a handheld device. Linbeck, Chatterjee and Varadhachary say TheraNas’s claims never made any sense to them, and the company’s founder, Elizabeth Holmes, is in federal court this week fighting federal fraud charges. In contrast to TheraNas, Brevitest only claims to conduct one test per fingerstick and will release its testing data for outside review, Chatterjee said.

Brevitest will never replace the broad tests best done by a central lab, for things like annual physicals, because they require a large amount

of blood and the big machines are more efficient, Linbeck said. But the team foresees doctors and clinics using Brevitest to routinely monitor patients with compromised immune systems or to track specific biomarkers for cancer and other infectious diseases.

Most breakthrough research in health care and medical devices never makes it out of the lab because investors lack the patience required to bring a product to market.



Leo Linbeck III, left, founder and chairman of Fannin Innovation Studio and managing partner Atul Varadhachary, right, develop medical technologies along with their portfolio companies like Procyron. Wednesday, Nov. 12, 2014, in Houston. (Photo/Marie D. De Jesus, Staff / Houston Chronicle)

The company’s strategy of licensing bio-medical discoveries and gathering researchers under the studio’s umbrella to keep administrative overhead low until they had a commercial product. Linbeck said the investor community needs to have more conversations about the best way to finance life science startups.

“There’s a lot of misconceptions about the way that this stuff works,” he said. “Having been down in the weeds, I have a greater level of humility and respect around just how difficult this is. The human body doesn’t like to be tinkered with, which is great news for us from an evolutionary standpoint, but it’s not so great from a medical innovation development standpoint.” From an investor perspective, Linbeck said the most significant challenge was finding the right people to manage the transition from the research lab to a for-profit company. Fannin recruits and trains people with medical and life science skills who are interested in entrepreneurship.

“This is about making a big pile of money because that’s also what will sustain us over the long haul,” Linbeck said. “That means that we get involved early, and it takes longer, but when the payoff happens, I think it’ll be really-big multiples.”

Energy projects and technology investments can pay off big, too, and take less time. But Linbeck said he doesn’t mind the wait to build a business that saves lives.

“Anything really important and high impact takes a decade,” he said. “It just does.” (Courtesy houstonchronicle.com)

COMMUNITY